EUVIMEDEUVIMED entdecken
Crossref

Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia

Eitan Kugler iD, Hagop Kantarjian iD, Elias Jabbour iD, Niranjan Khaire, Nicholas J Short iD, Tapan M Kadia iD, Fadi G Haddad iD, Koji Sasaki iD, Rashmi Kanagal Shamanna iD, Rebecca Garris, Farhad Ravandi, Nitin Jain iD

Cancer · 2025

DOI: 10.1002/cncr.35773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Eitan Kugler und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols, Philadelphia Chromosome, Protein Kinase Inhibitors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Leukemia and Lymphoma Society Career Development Award, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The BCR::ABL1 tyrosine kinase inhibitors (TKIs) have significantly improved the outcomes of patients with Philadelphia chromosome (Ph)‐positive acute lymphoblastic leukemia (ALL). However, the optimal duration of TKI therapy in patients who achieve a complete molecular response (CMR; undetectable BCR::ABL1 transcripts) and who do not undergo allogeneic stem cell transplantation (allo‐SCT) remains undefined.

Methods

The authors conducted a retrospective analysis of patients with Ph‐positive ALL in first complete remission who achieved a CMR and discontinued TKI therapy, most commonly due to treatment‐related side effects.

Results

In total, 14 patients were identified. The regimen of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high‐dose methotrexate and cytarabine was the primary backbone chemotherapy and was received by 12 patients (86%) combined with either imatinib (14%), dasatinib (43%), or ponatinib (29%) during induction. Two patients received blinatumomab and ponatinib. The median duration of TKI therapy was 60 months. The median CMR duration before TKI discontinuation was 46.1 months (range, 2.7–121.3 months). After a median follow‐up of 42.5 months from TKI discontinuation, three patients (21%) experienced relapse (two molecular, one morphologic), whereas 11 patients (79%) maintained treatment‐free remission. The median time to relapse was 6.4 months (range, 4–16 months), and two of three relapsed patients regained CMR after resuming TKI therapy. Importantly, none of the six patients with a CMR duration >48 months before TKI discontinuation relapsed.

Conclusions

The current findings suggest that TKI discontinuation may be safe for highly selected patients with Ph‐positive ALL in first complete remission who maintain CMR for at least 48 months. Larger studies are needed to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsPhiladelphia ChromosomeProtein Kinase InhibitorsHumansMaleFemaleAdultMiddle AgedRemission InductionRetrospective StudiesYoung AdultDasatinibAdolescentImatinib MesylateFusion Proteins, bcr-ablDoxorubicinDexamethasoneVincristineAgedCyclophosphamideMethotrexateImidazolesCytarabine

Stichwörter der Autor:innen

Philadelphia chromosome‐positive (Ph‐positive)acute lymphoblastic leukemia (ALL)treatment‐free remission (TFR)tyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsDasatinibImatinib MesylateFusion Proteins, bcr-ablDoxorubicinDexamethasoneVincristineponatinibCyclophosphamideMethotrexate

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Eitan Kugler, Hagop Kantarjian, Elias Jabbour, Nicholas J Short, Tapan M Kadia, Fadi G Haddad, Koji Sasaki, Rashmi Kanagal Shamanna, Nitin Jain

Förderung

  • Leukemia and Lymphoma Society Career Development Award
  • NCI NIH HHS

Zitieren

APA

Kugler, E., Kantarjian, H., Jabbour, E., Khaire, N., Short, N. J., Kadia, T. M., Haddad, F. G., Sasaki, K., Kanagal Shamanna, R., Garris, R., Ravandi, F., & Jain, N. (2025). Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia. Cancer. https://doi.org/10.1002/cncr.35773

Vancouver

Kugler E, Kantarjian H, Jabbour E, Khaire N, Short NJ, Kadia TM, et al. Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia. Cancer. 2025. doi:10.1002/cncr.35773

BibTeX
@article{Kugler2025,
  author = {Kugler, Eitan and Kantarjian, Hagop and Jabbour, Elias and Khaire, Niranjan and Short, Nicholas J and Kadia, Tapan M and Haddad, Fadi G and Sasaki, Koji and Kanagal Shamanna, Rashmi and Garris, Rebecca and Ravandi, Farhad and Jain, Nitin},
  title = {Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35773}
}
Kostenlos starten →